BiographyDr. Yeh is a graduate of Harvard Medical School, and has also received graduate degrees in health policy from the London School of Hygiene and Tropical Medicine/Economics (jointly) and business administration from Oxford University. He completed residency at the MGH, cardiology fellowship at the University of California, San Francisco, and interventional cardiology fellowship at the MGH. Dr. Yeh is a member of the interventional cardiology staff, focusing on coronary interventional procedures, including transradial catheterization and recanalization of chronic total occlusions (CTO). He is the Co-Director of the MGH CTO Intervention Program, and specializes in complex coronary procedures, including those involving retrograde and antegrade dissection-reentry techniques. He is the Associate Director of the MGH Cardiac Intensive Care Unit.
His research examines real world outcomes and the comparative effectiveness of novel cardiovascular devices and therapies. He also serves as Medical Director for Trial Design at the Harvard Clinical Research Institute, where he is involved in the design of clinical trials and post-marketing studies of cardiovascular devices. Dr. Yeh's research is funded by the National Heart, Lung and Blood Institute, the American Heart Association, the Harvard Clinical Research Institute, and the Hassenfeld Scholars Program.
ResearchDr. Yeh leads a research group at the Massachusetts General Hospital focusing on cardiovascular outcomes research in the area of acute coronary syndromes, coronary revascularization, and cardiac device utilization.
Areas of interest include:
1) The development of prediction instruments used to support clinical decision-making and patient risk-stratification for cardiovascular procedures and therapies.
2) Exploiting natural experiments for comparing treatment effectiveness in observational research studies.
3) The development and critical evaluation of hospital quality and performance measures for cardiac procedures, including risk-adjusted mortality and readmission metrics for percutaneous coronary intervention.
4) The study of contemporary epidemiologic trends in coronary artery disease and their implications for the delivery of high quality, high value care.
For a complete list, see PubMed link
In General awards and honors
February is American Heart Month, and the spotlight is on heart health. Throughout this month, we will be featuring articles including discussions with physicians in the Massachusetts General Heart Center to learn more about the topics surrounding heart disease, the leading cause of death in the U.S. for both men and women.
New treatment option allows some coronary artery patients to "bypass" bypass surgery. Interventional cardiologists at the Institute for Heart, Vascular and Stroke Care at Mass General offer a less-invasive treatment with quicker recovery.
Massachussets General Hospital offers a minimally invasive procedure to treat chronic total occlusions (CTOs).
A new study finds that the use of drug-eluting stents after angioplasty bears little relationship to patients' predicted risk of restenosis (reblockage) of the treated coronary artery, the situation the devices are designed to prevent.